Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Nile Therapeutics has received the US Food and Drug Administration's (FDA) fast track designation for post-acute development program for Cenderitide.
Subscribe to our email newsletter
Nile intends to develop Cenderitide as an outpatient therapy to be delivered to acutely decompensated heart failure (ADHF) patients continuously for up to 90 days after discharge from the hospital.
Nile CEO Joshua Kazam said they are very pleased that the FDA has recognized Cenderitide’s potential to address an important unmet medical need for heart failure patients.